[Comment] Has the limit been reached in treatment of unresectable oesophageal squamous cell carcinoma?

SKYSCRAPER-08, a randomised, double-blind, placebo-controlled, phase 3 trial, marks a milestone in the treatment of oesophageal squamous cell carcinoma.1 Patients were randomly assigned to receive tiragolumab (a TIGIT inhibitor) plus atezolizumab (a PD-L1 inhibitor) and chemotherapy (paclitaxel and cisplatin) or to receive placebo and chemotherapy. Median progression-free survival was 6·2 months (95% CI 5·7–7·2) with tiragolumab plus atezolizumab versus 5·4 months (4·4–5·5) without (hazard ratio [HR] 0·56, 95% CI 0·45–0·70; p<0·0001), whereas median overall survival was 15·7 months (95% CI 13·3–20·4) versus 11·1 months (9·6–13·6; HR 0·70, 95% CI 0·55–0·88; p=0·0024).